ARCHIVES

Economic Analysis Finds Erlotinib Marginally Cost-Effective For NSCLC

This article is from The Cancer Letter archive.

Vol. 33 No. 2 | February 26, 2010

Download PDF Visit The Full Archive

Related Articles

New Immunotherapy Increased Survival Of Neuroblastoma In Phase III Trial

September 24, 2010

Ovarian Cancer Symptom Indices May Need to be Re-Evaluated

January 27, 2012

In Brief: Susan Hubbard Names Director Of International Cancer information Center; Includeds ICRDB, PDQ

September 14, 1984

Abstracts Deadline For Cancer Congress Extended To Dec. 31

December 13, 1985

UK Research Groups To Fund Virtual Tumor Bank

April 18, 2003

In Brief: Sporn Wins BMS Cancer Research Award; Dana-Farber To Try To Affect Teen Health

April 3, 1998